Spero Therapeutics Inc logo

SPRO

Spero Therapeutics Inc

$1.07

Earnings Summary

Revenue
$2.07Mn
Net Profits
$-32.83Mn
Net Profit Margins
-1586.71%

Highlights

Revenue:

Spero Therapeutics Inc’s revenue fell -71.66% since last year same period to $2.07Mn in the Q1 2022. On a quarterly growth basis, Spero Therapeutics Inc has generated -24.6% fall in its revenue since last 3-months.

Net Profits:

Spero Therapeutics Inc’s net profit fell -69.02% since last year same period to $-32.83Mn in the Q1 2022. On a quarterly growth basis, Spero Therapeutics Inc has generated -12.27% fall in its net profits since last 3-months.

Net Profit Margins:

Spero Therapeutics Inc’s net profit margin fell -496.35% since last year same period to -1586.71% in the Q1 2022. On a quarterly growth basis, Spero Therapeutics Inc has generated -48.9% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Spero Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.89
EPS Estimate Current Year
-0.89

Highlights

EPS Estimate Current Quarter:

Spero Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.89 - a -2.3% fall from last quarter’s estimates.

EPS Estimate Current Year:

Spero Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.89.

Key Ratios

Key ratios of the Spero Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.01
Return on Assets (ROA)
-0.64
Return on Equity (ROE)
-1.8
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Spero Therapeutics Inc’s earning per share (EPS) fell -53.03% since last year same period to -1.01 in the Q1 2022. This indicates that the Spero Therapeutics Inc has generated -53.03% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Spero Therapeutics Inc’s return on assets (ROA) stands at -0.64.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Spero Therapeutics Inc’s return on equity (ROE) stands at -1.8.

Dividend Per Share (DPS):

Spero Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.87
-1.01
-16.09%

Company Information

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Organisation
Spero Therapeutics Inc
Headquarters
Cambridge, Massachusetts, US
Employees
89
Industry
Health Technology
CEO
Ankit Mahadevia